<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer Research Journal &#187; Myeloma</title>
	<atom:link href="http://cancerresearchjournal.com/category/myeloma/feed/" rel="self" type="application/rss+xml" />
	<link>http://cancerresearchjournal.com</link>
	<description></description>
	<lastBuildDate>Tue, 21 Jul 2009 17:04:30 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Mayo Shows Cybor-D More Effective for Multiple Myeloma</title>
		<link>http://cancerresearchjournal.com/2007/12/14/mayo-shows-cybor-d-more-effective-for-multiple-myeloma/</link>
		<comments>http://cancerresearchjournal.com/2007/12/14/mayo-shows-cybor-d-more-effective-for-multiple-myeloma/#comments</comments>
		<pubDate>Fri, 14 Dec 2007 19:59:29 +0000</pubDate>
		<dc:creator>Lisa</dc:creator>
				<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[Podcasts]]></category>

		<guid isPermaLink="false">http://cancerresearchjournal.com/2007/12/14/mayo-shows-cybor-d-more-effective-for-multiple-myeloma/</guid>
		<description><![CDATA[A phase II trial conducted by researchers from the Mayo Clinic and Prince Margaret Hospital shows a new drug regimen is more effective than traditional treatments in helping newly-diagnosed patients with multiple myeloma.
The new treatment, known as Cybor-D, consists of cyclophosphamide, bortezomib and dexamethasone.  To arrive at their findings, the team administered the investigational [...]]]></description>
			<content:encoded><![CDATA[<!-- sphereit start --><p>A phase II <a href="http://clinicaltrials.gov/" rel="tag">trial</a> conducted by researchers from the <a href="http://www.mayoclinic.com/" rel="tag">Mayo Clinic</a> and <a href="http://www.uhn.ca/pmh/index.htm" rel="tag">Prince Margaret Hospital</a> shows a new <a href="http://seer.cancer.gov/tools/seerrx/" rel="tag">drug regimen</a> is more effective than traditional <a href="http://www.cancer.gov/cancertopics/treatment" rel="tag">treatments</a> in helping newly-diagnosed patients with <a href="http://myeloma.uams.edu/about-myeloma/pathology.asp" rel="tag">multiple myeloma</a>.</p>
<p>The new treatment, known as Cybor-D, consists of <a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682080.html" rel="tag">cyclophosphamide</a>, <a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a607007.html" rel="tag">bortezomib</a> and <a href="http://www.pharmgkb.org/do/serve?objId=PA449247&#038;objCls=Drug" rel="tag">dexamethasone</a>.  To arrive at their findings, the team administered the investigational Cybor-D treatments to 30 patients while 34 other patients received standard L-Dex treatments consisting of <a href="http://www.fda.gov/CDER/Drug/infopage/lenalidomide/default.htm" rel="tag">lenalidomide</a>-dexamethasone.</p>
<p>Their study revealed newly-diagnosed <a href="http://www.multiplemyeloma.org/" rel="tag">multiple myeloma patients</a> receiving Cybor-D treatments responded better than those receiving L-Dex therapy.  In a majority of cases, Cybor-D recipients experienced a rapid reduction in <a href="http://www.neuro.wustl.edu/neuromuscular/antibody/mprotein.htm" rel="tag">M protein</a> antibodies which can build up in <a href="http://www.marrow.org/" rel="tag">bone marrow</a>, thicken <a href="http://www.kidshealth.org/parent/general/body_basics/blood.html" rel="tag">blood</a>, or cause <a href="http://www.lifeoptions.org/kidneyinfo/ckdinfo.php?page=3" rel="tag">kidney damage</a>.</p>
<p><a href="http://ndc.mayo.edu/mayo/research/staff/reeder_cb.cfm" rel="tag">Dr Craig B Reeder</a> presented the group&#8217;s findings at the <a href="http://www.hematology.org/" rel="tag">American Society of Hematology</a>’s <a href="http://www.hematology.org/meetings/2007/index.cfm" rel="tag">annual meeting</a> in <a href="http://www.atlantaga.gov/" rel="tag">Atlanta</a>, <a href="http://www.georgia.gov/00/home/0,2061,4802,00.html;jsessionid=31A0EB4152BA91EEC88F6F29AC12B542">Georgia</a>, held December 8-11, 2007.</p>
<p>Source:  <a href="http://www.mayoclinic.org/news2007-sct/4377.html?rss-feedid=9" rel="tag">Mayo Foundation for Medical Education and Research</a> </p>
<p>Related Links:  <a href="http://www.bio-medicine.org/medicine-news-1/New-therapeutic-options-for-newly-diagnosed-multiple-myeloma-patients-7965-1/" rel="tag">Bio-medicine.org</a>; <a href="http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_multiple_myeloma_30.asp" rel="tag">American Cancer Society</a>; <a href="http://www.labtestsonline.org/understanding/conditions/mult_myeloma-2.html" rel="tag">labtestsonline.org</a> </p>
<p>Related Podcast: <a href="http://www.nccn.org/interactive/podcasts/mp3/hema_2007/how_treat_patients_progress_relapse.mp3" rel="tag">Multiple Myeloma:  How to Treat Patients that Progress or Relapse</a> from the <a href="http://www.nccn.org/default.asp" rel="tag">National Comprehensive Cancer Network</a> </p>
<p>Tags:  <a href="http://www.leukemia-lymphoma.org/all_page?item_id=4235" rel="tag">blood cancers</a>; <a href="http://cancercenter.mayo.edu/" rel="tag">Mayo Clinic Cancer Center</a>; <a href="http://www.toronto.ca/" rel="tag">Toronto</a>; <a href="http://www.asco.org/" rel="tag">oncology</a>; <a href="http://www.cancer.gov/cancertopics/chemotherapy-and-you" rel="tag">chemotherapy</a>; <a href="http://www.cityofhope.org/CCC/Research/HematologicMalignancies.htm" rel="tag">hematologic malignancies</a> </p>
<!-- sphereit end -->]]></content:encoded>
			<wfw:commentRss>http://cancerresearchjournal.com/2007/12/14/mayo-shows-cybor-d-more-effective-for-multiple-myeloma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
<enclosure url="http://www.nccn.org/interactive/podcasts/mp3/hema_2007/how_treat_patients_progress_relapse.mp3" length="6518550" type="audio/mpeg" />
		</item>
	</channel>
</rss>
